Stockscreener 앱 받기
4.945
11.07%
0.495
전일 마감가:
$4.45
열려 있는:
$4.54
하루 거래량:
1.95M
Relative Volume:
0.63
시가총액:
$441.69M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-1.9093
EPS:
-2.59
순현금흐름:
$-134.39M
1주 성능:
+13.36%
1개월 성능:
-4.77%
6개월 성능:
-30.97%
1년 성능:
-4.77%
1일 변동 폭
$4.50
$5.10
1주일 범위
$3.89
$5.10
52주 변동 폭
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
명칭
Verve Therapeutics Inc
전화
(978) 501-3026
주소
201 BROOKLINE AVENUE, BOSTON
VERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
4.955 | 382.42M | 20.65M | -192.65M | -134.39M | -2.59 |
|
ONC
Beone Medicines Ltd Adr
|
245.90 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.19 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.55 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
501.35 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-10-06 | 개시 | Credit Suisse | Neutral |
| 2022-08-25 | 업그레이드 | Stifel | Hold → Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-07-12 | 개시 | Guggenheim | Buy |
| 2021-07-12 | 개시 | JP Morgan | Neutral |
| 2021-07-12 | 개시 | Jefferies | Buy |
| 2021-07-12 | 개시 | William Blair | Outperform |
모두보기
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st
Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance
Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World
Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics: Q1 Earnings Snapshot - CT Insider
Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus
Verve Therapeutics, Inc. SEC 10-Q Report - TradingView
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances Clinical Trials | VERV Stock News - GuruFocus
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Wednesday - Defense World
Stifel Financial Corp Purchases 9,736 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Tower Research Capital LLC TRC Lowers Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - AOL.com
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
(VERV) Investment Analysis - news.stocktradersdaily.com
Wells Fargo & Company MN Boosts Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Invesco Ltd. Buys 3,080 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release Distribution & PR Platform - ACCESS Newswire
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics Inc (VERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verve Therapeutics Inc 주식 (VERV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '25 |
Sale |
4.15 |
2,777 |
11,525 |
17,420 |
| Ashe Andrew D. | See Remarks |
Apr 02 '25 |
Sale |
4.15 |
2,681 |
11,126 |
348,828 |
| Politi Jason | Chief Technical Ops. Off. |
Apr 02 '25 |
Sale |
4.15 |
3,235 |
13,425 |
14,226 |
| Dorval Allison | Chief Financial Officer |
Apr 02 '25 |
Sale |
4.15 |
3,350 |
13,903 |
13,280 |
| Lister Troy | Chief Scientific Officer |
Apr 02 '25 |
Sale |
4.15 |
2,189 |
9,084 |
6,952 |
| Dorval Allison | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.64 |
555 |
3,130 |
5,380 |
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
1.76%
0.89%
자본화:
|
볼륨(24시간):